Anesthesiological Strategies in Elective Craniotomy (Neuromorfeo)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This protocol, NeuroMorfeo, aims to assess equivalence between volatile and intravenous anesthetics for neurosurgical procedures.
| Condition | Intervention | Phase |
|---|---|---|
|
Anesthesia Craniotomy Neurosurgery |
Drug: Sevoflurane + Fentanyl Drug: Sevoflurane + Remifentanyl Drug: Propofol + Remifentanyl |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial |
- Post-anesthesia awaking time, assessed as the interval (min:sec)required to reach an ALDRETE score ≥ 9 [ Time Frame: From estubation to aldrete score ≥ 9 ] [ Designated as safety issue: No ]
- Neurovegetative stress [ Time Frame: From induction of anesthesia to 24 hours after surgery ] [ Designated as safety issue: No ]
- Intraoperative and post-operative adverse events assessment [ Time Frame: From induction of anesthesia to 24 hours after surgery ] [ Designated as safety issue: Yes ]
- Brain relaxation evaluated by a blinded neurosurgeon [ Time Frame: From induction of anesthesia to 24 hours after surgery ] [ Designated as safety issue: No ]
- Patient's satisfaction [ Time Frame: From induction of anesthesia to 24 hours after surgery ] [ Designated as safety issue: No ]
- Costs of the three strategies [ Time Frame: From induction of anesthesia to end of surgery ] [ Designated as safety issue: No ]
| Enrollment: | 411 |
| Study Start Date: | December 2007 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: IF
Sevoflurane (Inhalation)+Fentanyl
|
Drug: Sevoflurane + Fentanyl
Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
|
|
Experimental: IR
Sevoflurane (Inhalation)+Remifentanyl
|
Drug: Sevoflurane + Remifentanyl
Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
|
|
Experimental: ER
Propofol (Endovenous)+ Remifentanyl
|
Drug: Propofol + Remifentanyl
Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
|
Detailed Description:
NeuroMorfeo is a multicenter, randomized, open label, controlled trial, based on an equivalence design. Patients aged between 18 and 75 years, scheduled for a elective craniotomy for supratentorial lesion without signs of intracranial hypertension, in good physical state evaluated with the ASA (I-III) and Glasgow Coma Scale (GCS) equal to 15, will be randomly assigned to one of three anesthesiological strategies (two VA arms, sevoflurane + fentanyl or sevoflurane + remifentanil, and one IA, propofol + remifentanil). The equivalence between intravenous and volatile-based neuroanesthesia will be evaluated by comparing the intervals required to reach, after anesthesia discontinuation, a modified Aldrete score ≥ 9 (primary end-point). Two statistical comparisons have been planned: 1) sevoflurane + fentanyl vs. propofol + remifentanil; 2) sevoflurane + remifentanil vs. propofol + remifentanil.
Secondary end-points include: an assessment of neurovegetative stress based on (a) measurement urinary catecholamines and plasma and urinary cortisol and (b) estimate of sympathetic/parasympathetic balance by power spectrum analyses of electrocardiographic tracings recorded during anesthesia; intraoperative adverse events (i.e. hypotension, hypertension, requirement of osmotic agents or/and hyperventilation for controlling brain swelling); evaluation of surgical field; postoperative adverse events (as seizures, cough, shivering, agitation, postoperative hematoma and postoperative pain); patient's satisfaction and an analysis of costs.
411 patients will be recruited in 14 different Italian centers during an 18-month period.
The recruitment started December 20th, 2007 and up to 11th March 2009.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Patient scheduled for elective intracranial surgery under general anesthesia for a supratentorial mass lesion in the next 24 hours;
- Physical state, evaluated with the ASA (American Society of Anesthesiologists ) classification I (normal healthy patient), II (patient with mild systemic disease), or III (patient with severe systemic disease);
- Age 18-75 years;
- Normal preoperative level of consciousness, i.e. Glasgow Coma Scale (GCS) = 15;
- No signs of intracranial hypertension.
Exclusion criteria:
- Severe cardiovascular pathology, as uncontrolled arterial hypertension, documented reduced coronary reserve.
- Renal or liver disease precluding the use of either anesthetic technique.
- Pregnancy .
- Known allergies to any anesthetic agent.
- Reduced preoperative level of consciousness, i.e.
- Glasgow Coma Scale (GCS) < 15.
- Body weight greater than 120 kg.
- History of drug abuse or psychiatric conditions.
- Documented disturbance of the hypothalamic region.Refusal to sign consent form.
- Participation in other clinical trials.
- Delayed awakening, because, due to the location or size of the lesion, postoperative sedation and mechanical ventilation are planned.
Contacts and Locations| Italy | |
| Policlinico Consorziale di Bari | |
| Bari, Italy | |
| Ospedale Bellaria Bologna | |
| Bologna, Italy, 40100 | |
| Istituto di Ricerche Farmacologiche Mario Negri - Dipartimento di Ricerca Cardiovascolare- | |
| Milan, Italy, 20100 | |
| IRCCS Fondazione San Raffaele Milano | |
| Milan, Italy, 20100 | |
| Azienda Ospedaliera San Gerardo | |
| Monza, Italy, 20052 | |
| Ospedale Maggiore della Carità di Novara | |
| Novara, Italy, 28100 | |
| Ospedale di Padova | |
| Padua, Italy, 35128 | |
| Azienda Ospedaliera di Parma | |
| Parma, Italy, 43100 | |
| Policlinico "A. Gemelli" Roma | |
| Rome, Italy | |
| Policlinico "Umberto I" Roma | |
| Rome, Italy | |
| Azienda Universitaria Senese | |
| Siena, Italy, 53100 | |
| Ospedale San giovanni Battista Torino | |
| Turin, Italy | |
| Ospedale San Giovanni Bosco Torino | |
| Turin, Italy, 10057 | |
| Ospedale di Circolo e Fondazione Macchi Varese | |
| Varese, Italy, 21100 | |
| Azienda Ospedaliera Universitaria di Verona | |
| Verona, Italy, 37121 | |
| Principal Investigator: | Giuseppe Citerio, MD | Azienda Ospedaliera San Gerardo Monza |
| Study Chair: | Antonio Pesenti, MD | Università delgi Studi Milano Bicocca |
| Study Chair: | Maria Grazia Franzosi, PhD | Istituto Di Ricerche Farmacologiche Mario Negri |
| Study Chair: | Roberto Latini, MD | Istituto Di Ricerche Farmacologiche Mario Negri |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dott. Giuseppe Citerio, MD, Azienda Ospedaliera San Gerardo di Monza |
| ClinicalTrials.gov Identifier: | NCT00741351 History of Changes |
| Other Study ID Numbers: | EudraCT number 2007-005279-32, AIFA FARM6FKJKK |
| Study First Received: | August 22, 2008 |
| Last Updated: | September 7, 2011 |
| Health Authority: | Italy: The Italian Medicines Agency |
Keywords provided by Azienda Ospedaliera San Gerardo di Monza:
|
Anesthesia Craniotomy Neurosurgery |
Additional relevant MeSH terms:
|
Fentanyl Propofol Remifentanil Sevoflurane Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Narcotics Central Nervous System Depressants Physiological Effects of Drugs |
Analgesics Sensory System Agents Peripheral Nervous System Agents Anesthetics, Intravenous Anesthetics, General Anesthetics Analgesics, Opioid Hypnotics and Sedatives Platelet Aggregation Inhibitors Hematologic Agents Anesthetics, Inhalation |
ClinicalTrials.gov processed this record on May 22, 2013